Compare LVWR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVWR | SABS |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.4M | 293.9M |
| IPO Year | 2022 | 2020 |
| Metric | LVWR | SABS |
|---|---|---|
| Price | $0.54 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.64 |
| AVG Volume (30 Days) | 327.3K | ★ 656.9K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.57 | ★ 78.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,672,000.00 | N/A |
| Revenue This Year | $604.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $2.44 |
| 52 Week High | $5.13 | $5.15 |
| Indicator | LVWR | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 47.67 |
| Support Level | N/A | $2.44 |
| Resistance Level | $1.71 | $4.06 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 2.13 | 51.55 |
LiveWire Group Inc is an all-electric vehicle company. It sells electric vehicles and related parts and accessories and apparel in the United States and certain international markets. The company's segment includes Electric Motorcycles and STACYC. Electric Motorcycles segment sells electric motorcycles, related parts and accessories and apparel in the United States and certain international markets; STACYC segment sells electric balance bikes for kids, related parts and accessories and apparel in the United States and certain international markets. LiveWire generates revenue from the sale of electric motorcycles, Parts, accessories and apparel. Majority of revenue is from USA.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.